Exelixis said it was notified by the Food and Drug Administration that its treatment for advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic will not be discussed at a meeting.

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

The Phase III trial successfully saw patients achieving clinical remission and stopping rectal bleeding within 28 days.

The prosecutor-led program continues her look into juvenile justice. It also continues a state-wide examination of the impact ...

Grieving parents of children killed by fentanyl pills say the Trump administration has the potential to address the nation's drug epidemic.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

On January 8, 2025, the Department of Justice (“DOJ”) published its Final Rule to implement President Biden’s Executive Order 14117, ...

An Interview with Innocan Pharma’s CEO, Iris Bincovich. Innocan Pharma is gaining attention for its innovative pain relief ...

Multi-year program advancing translational medical science research and educationCAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today celebrates ...